June 18, 2014 - CLL- Current and Emerging Therapies
- The goal of CLL treatment
- How staging influences personalized treatment planning
- Current treatment options for CLL
- Emerging therapies and clinical trials for CLL
- Side effects management
- The importance of open communication with your treatment team
Thomas J. Kipps, MD, PhD
Professor of Medicine
Division of Hematology-Oncology
Deputy Director for Research
UC San Diego Moores Cancer Center
La Jolla, CA
Questions Asked by the CLL Community:
- How frequently should a FISH test be done for an unmutated patient?
- Have you seen many cases of CLL patients who also have angioedema?
- How high can your white blood count get without needing treatment?
- Can body pain be related to CLL?
- Is it common to have a local oncologist and in addition have a CLL expert oversee your healthcare treatment? Also, would most insurance plans cover this arrangement?
- What is the role of allogeneic transplantation in CLL?
- Please address how staging influences personal treatment planning. I was diagnosed with Stage 0 CLL and my blood counts have remained stable. Should I be proactive and consider treatment at this time, or should I keep with the watchful waiting program?
- I was wondering how trisomy 12 and deletion 6q affect treatment and prognosis?
- Because of a lack of long-term studies on ibrutinib and idelalisib, do you recommend these drugs for patients in their 50s or early 60s who have not responded to FCR?
- My mother is 80 years old and was diagnosed with CLL B-cell type, Stage 0. Will her age impact her doctor's decision regarding which course of treatment to pursue?
- How can I find out about clinical trials or discuss clinical trials with my doctor, who seems to have just enough time to discuss my current treatment with me?
- If I start falling out of remission, do I need a new FISH test?
- Are you aware of any further research into the efficacy of EGCG as found in green tea, or any other research focusing on holistic treatments for CLL?
Sponsors and Supporters
This patient education program is supported by grants from Genentech Inc. and Biogen Idec and Pharmacyclics, Inc. and Janssen Biotech, Inc.
Continuing Education is supported by Pharmacyclics, Inc. and Janssen Biotech, Inc.